Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis
← catalyst calendarNCT07095465 · readout ≤ 924 d
Sponsored by ACADIA Pharmaceuticals Inc. (industry) · ACAD — their whole pipeline →.
Phase
Phase 3
Status
Enrolling by invitation
Study type
Interventional
Design
Na · None · Treatment
Enrollment
126estimated
Sites
30
Countries
Bulgaria, Czechia, France +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-11-14 | actual | When the study began enrolling |
| Primary completion | Feb 2029 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Mar 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2025-07-31 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Lewy Body Dementia Psychosis
Intervention
- Drug: ACP-204 — also filed as ACP-204 Tartrate
Primary outcome
what the primary-completion date above is the date OFProportion of subjects who experience treatment-emergent adverse events (TEAEs)
measured 52 weeks
Permalink · ACAD's whole pipeline · Catalyst calendar · Every registered study · What changed